As these effects are closely related to cognition, we believethat the results of this study have strengthened the continued evaluationof the somatostatin peptide as a therapeutic option to amelioratethe cognitive dysfunction presented in Alzheimer’s disease. The gene discussed is SST; the disease is Alzheimer disease.